| Patents for A61P 17 - Drugs for dermatological disorders (106,455) |
|---|
| 08/05/2003 | US6603012 RAR selective retinoid agonists |
| 08/05/2003 | US6603008 Sulfamoylheleroaryl pyrazole compounds as anti-inflammatory/analgesic agents |
| 08/05/2003 | US6602914 Treatment of a disease that is mediated by the expression or suppression of a redox sensitive gene, for example MCP-1, IL-6 and thrombin receptor; antiinflammatory agents; cardio-vascular disorders; atherosclerosis; immunology |
| 08/05/2003 | US6602881 Anti-inflammatory uses of manzamines |
| 08/05/2003 | US6602872 Substituted pyridazines having cytokine inhibitory activity |
| 08/05/2003 | US6602869 Compounds derived from benzoic acid esters, composition containing said compounds and use thereof |
| 08/05/2003 | US6602863 Irreversible inhibitors of tyrosine kinases |
| 08/05/2003 | US6602856 Antagonists of alpha-melanocyte stimulating hormone and methods based thereon |
| 08/05/2003 | US6602509 Compound and method for the prevention and/or the treatment of allergy |
| 07/31/2003 | WO2003063179A1 Radiation protector and utilization thereof |
| 07/31/2003 | WO2003062392A2 Methods of treating conditions associated with an edg receptor |
| 07/31/2003 | WO2003062278A1 MONOCLONAL ANTIBODIES AGAINST EXTRACELLULAR LOOPS OF C5aR |
| 07/31/2003 | WO2003062275A1 Glycoisoforms of adiponectin and uses thereof |
| 07/31/2003 | WO2003062271A1 Peptides and nucleic acids of the cathelicidin family, derived from fish, and uses thereof |
| 07/31/2003 | WO2003062252A1 Edg receptor agonists |
| 07/31/2003 | WO2003062248A2 N-(benzyl)aminoalkylcarboxylates, phosphinates, phosphonates and tetrazoles as edg receptor agonists |
| 07/31/2003 | WO2003062241A1 Fused heterocyclic succinimidecompounds and analogs thereof, modulators of nuclear hormone receptor function |
| 07/31/2003 | WO2003062236A1 2-(PYRIDIN-2-YLAMINO)-PYRIDO[2,3d]PYRIMIDIN-7-ONES |
| 07/31/2003 | WO2003062209A2 Substituted quinazolin-4-ylamine analogues as modulators of capsaicin |
| 07/31/2003 | WO2003062191A1 N-(4-substituted phenyl)-anthranilic acid hydroxamate esters |
| 07/31/2003 | WO2003062189A1 N-(4-substituted phenyl)-anthranilic acid hydroxamate esters |
| 07/31/2003 | WO2003061768A2 Use of a compound inactivating the kinase a protein in a composition containing a cosmetically acceptable medium in order to lighten the skin |
| 07/31/2003 | WO2003061766A1 Composition based on etyllinoleate and triethylcitrate for the treatment of seborrhea and acne |
| 07/31/2003 | WO2003061721A1 Film-forming compositions and methods |
| 07/31/2003 | WO2003061713A1 Nsaid-containing topical formulations that demonstrate chemopreventive activity |
| 07/31/2003 | WO2003061699A1 Remedies for allergic diseases |
| 07/31/2003 | WO2003061686A1 Therapeutic application of g-csf, gm-csf and scf |
| 07/31/2003 | WO2003061667A1 Pharmaceutically acceptable phosphate-glycerol carrying bodies |
| 07/31/2003 | WO2003061666A1 Phospholipid bodies and use thereof in the treatment of inflammatory and autoimmune diseases |
| 07/31/2003 | WO2003061659A1 Treating stress response with chemokine receptor ccr5 modulators |
| 07/31/2003 | WO2003061653A1 3-(imidazolyl)-2-aminopropanoic acids for use as tafi-a inhibitors for the treatment of thrombotic diseases |
| 07/31/2003 | WO2003061652A1 3-(imidazolyl)-2-alkoxypropanoic acids as tafia inhibitors |
| 07/31/2003 | WO2003061620A2 Peptide-carrying bodies for immune response |
| 07/31/2003 | WO2003061580A2 Alteration of rab38 function to modulate mammalian pigmentation |
| 07/31/2003 | WO2003061362A2 Methods and compositions for treating polycystic ovary syndrome |
| 07/31/2003 | WO2003047516A3 Pyrimidine compounds |
| 07/31/2003 | WO2003041703A3 Use of a flavonoid for the treatment of burns |
| 07/31/2003 | WO2003035679A3 Molecules |
| 07/31/2003 | WO2003035668A3 Novel anti-inflammatory androstane derivatives -17-carboxy-lactone substituted steroids with an aryl-carboxylic ester in position 17.alpha |
| 07/31/2003 | WO2003024388A3 Methods and compositions for treating and preventing skin disorders using binding agents specific for psma |
| 07/31/2003 | WO2003022235A3 Water-in-silicone emulsions |
| 07/31/2003 | WO2003018545B1 24-sulfur-substituted analogs of 1α,25-dihydroxy vitamin d¿3? |
| 07/31/2003 | WO2003006495A3 Human papillomavirus e2 transactivation domain/inhibitor co-crystal and x-ray coordinates defining the inhibitor-binding pocket |
| 07/31/2003 | WO2003002596A3 Use of dipeptidyl peptidase iv inhibitors as therapeutics for neurological disorders |
| 07/31/2003 | WO2002094202B1 Methods for protecting allogeneic islet transplant using soluble ctla4 mutant molecules |
| 07/31/2003 | WO2002068421A3 Tricyclic compounds and their analogs as inhibitors of cytokine signaling |
| 07/31/2003 | WO2002062762A3 Potassium channel openers |
| 07/31/2003 | WO2002060875A8 Nicotinamide biaryl derivatives useful as inhibitors of pde4 isozymes |
| 07/31/2003 | WO2002060464A3 Compositions containing an active fraction isolated from hedyotis diffusae and methods of use |
| 07/31/2003 | WO2002058716A3 Treatment of inflammatory bowel disease using growth factors |
| 07/31/2003 | WO2002047730A3 Intracellular delivery of charged therapeutic moieties to nerve cells by means of targeting proteins |
| 07/31/2003 | WO2002029038A3 Novel proteins and nucleic acids encoding same and antibodies directed against these proteins |
| 07/31/2003 | WO2002018361A3 Compounds having activity as inhibitors of cytochrome p450rai |
| 07/31/2003 | WO2001098348A3 Regulation of cellproliferation and differentiation using topically applied peptides |
| 07/31/2003 | US20030144529 Treating p38 kinase mediated disorders. Compounds of particular interest are defined by Formula I Mitogen-activated protein kinases (MAP) is a family of proline- directed serine/threonine kinases that activate their |
| 07/31/2003 | US20030144510 Preparation of pharmaceutical salts |
| 07/31/2003 | US20030144363 Hydroxystilbene compounds for reducing/inhibiting protein glycation |
| 07/31/2003 | US20030144359 Dermatological use and a dermatological preparation |
| 07/31/2003 | US20030144347 Method for treating autoimmune disease |
| 07/31/2003 | US20030144346 Methods and compositions for regulation of 5-alpha reductase activity |
| 07/31/2003 | US20030144337 Pyrazole-derived kinase inhibitors and uses thereof |
| 07/31/2003 | US20030144335 Nitroimidazole compound for allergic conjunctivitis or allergic rhinitis |
| 07/31/2003 | US20030144331 p53 inhibitors and therapeutic use of the same |
| 07/31/2003 | US20030144328 Compounds which inhibit leukocyte adhesion mediated by VLA-4 |
| 07/31/2003 | US20030144311 Propanoic acid derivatives as intergrin receptor antagonists |
| 07/31/2003 | US20030144303 Aminopyrimidine and aminopyridine anti-inflammation agents |
| 07/31/2003 | US20030144302 Process for making substituted pyrazoles |
| 07/31/2003 | US20030144300 Pyrimidine carboxamides useful as inhibitors of pde4 isozymes |
| 07/31/2003 | US20030144298 Therapeutic combinations of antihypertensive and antiangiogenics agents |
| 07/31/2003 | US20030144294 Antiproliferative or anticarcinogenic agents comprising reaction products of ninhydrin or benzo(f)ninhydrin with 1,5-diaminotetrazole; enzyme inhibitors |
| 07/31/2003 | US20030144293 N-alkyl-adamantyl triazinyl benzamide derivatives |
| 07/31/2003 | US20030144286 Nitrogen compounds such as 3-nitro-N-(1H-benzoimidazol-2-yl)-benzamide, used as nonsteroidal antiinflammatory agents, immunology or interleukin receptor associated kinase (IRAK) modulators; rheumatic diseases; multiple sclerosis |
| 07/31/2003 | US20030144283 Amide substituted imidazoquinolines |
| 07/31/2003 | US20030144281 Substituted benzimidazole compounds |
| 07/31/2003 | US20030144280 Heterocyclic imines, used as cyclooxygenase inhibitors, administered as inflammatory and pain relievers in disorders such as arthritis, neurodegeneration or cancer in mammals |
| 07/31/2003 | US20030144279 5-Heterocyclo-pyrazoles |
| 07/31/2003 | US20030144276 Heterocycle-containing carboxylic acid derivative and drug containing the same |
| 07/31/2003 | US20030144274 Preferential enzyme inhibitors such as 3-(4-Methoxyphenyl)-prop-1-ynyl)-N-(4-carboxybenzyl)benzamide, used for prophylaxis of degenerative diseases including cancer and arthritis |
| 07/31/2003 | US20030144270 Neurokinin receptor antagonists comprising heterocyclic amides used as antiemetics, antidepressants and/or antitussive agents |
| 07/31/2003 | US20030144267 Novel compounds |
| 07/31/2003 | US20030144253 Useful for treating or preventing neuronal damage associated with neurological diseases |
| 07/31/2003 | US20030144250 Triazole derivatives useful in therapy |
| 07/31/2003 | US20030144203 Methods for slowing senescence and treating and preventing diseases associated with senescence |
| 07/31/2003 | US20030144180 Contains as active ingredient a therapeutically effective amount of agent for either enhancing protein kinase c production and/or activation |
| 07/31/2003 | US20030143739 Composition of restricted cancer cells which produce cancer cell proliferation suppressive materials, and uses thereof |
| 07/31/2003 | US20030143676 Receptor polypeptides and polynucleotides encoding such polypeptides; for treating a disorder characterized by an elevated level of osteopontin |
| 07/31/2003 | US20030143633 Factors participating in degranulation of mast cells, dnas encoding the same, method of screening of these factors and the inhibitors |
| 07/31/2003 | US20030143626 Such as cyclin-dependent kinases and/or bax genes/proteins covalently linked to platform compound (thioredoxin); drug screening |
| 07/31/2003 | US20030143589 Drug metabolizing enzymes |
| 07/31/2003 | US20030143559 A modified estrogen receptor alpha ligand binding domain containing an amino acid modification in region 1, at region 2, or atleast one amino acid modifiation in both of regions, and these domain interacts with a nonendogenous ligand |
| 07/31/2003 | US20030143288 Topical anti-inflammatory compositions and methods of reducing inflammation |
| 07/31/2003 | US20030143281 Composition of restricted cancer cells which produce cancer cell proliferation suppressive materials, and uses thereof |
| 07/31/2003 | US20030143275 Cosmetic and/or dermatological composition containing at least one oxidation-sensitive hydrophilic active principle and at least one N-vinylimidazole polymer or copolymer |
| 07/31/2003 | US20030143271 For therapy and prophylaxis of cyclooxygenase-2 mediated disorder and for providing cardioprotection |
| 07/31/2003 | US20030143246 Ganoderma lucidum spores for treatment of autoimmune diseases |
| 07/31/2003 | US20030143207 Remodeling of tissues and organ |
| 07/31/2003 | US20030143192 Chemokine beta-7 |
| 07/31/2003 | US20030143185 Polymer conjugates of protein kinase C inhibitors |
| 07/31/2003 | US20030143165 Regularly applying a topical formulation to the skin of patient, formulation containing a pharmaceutically effective amount of a non- steroidal anti-inflammatory drug |
| 07/31/2003 | CA2476773A1 Monoclonal antibodies against extracellular loops of c5ar |